Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow Vanda Pharmaceuticals Inc. ( VNDA ) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDT Company Participants Kevin Moran - Senior VP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman of The Board Daniel McGuire - Senior VP, General Counsel & Secretary Conference Call Participants Jan Z. Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Lin Tsai - Jefferies LLC, Research Division Presentation Operator Good afternoon and welcome to the second quarter 2026 Vanda Pharmaceuticals Incorporated earnings conference call. I am [ Franz ], and I'll be the operator assisting you today. [Operator Instructions] I would now like to turn the call over to Vanda's Chief Financial Officer, Kevin Moran. Kevin Moran Senior VP, CFO & Treasurer Thank you, [ Franz ]. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' second quarter 2026 performance. Our second quarter 2026 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board, and Daniel McGuire, our General Counsel. Following my introductory remarks, Mihael will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's discussion and analysis of financial condition and results of operations, sections of our most recent